Literature DB >> 28616602

Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.

Abhishek Mitra1, Shailesh V Shrikhande1, Bhawna Sirohi2.   

Abstract

Entities:  

Year:  2017        PMID： 28616602      PMCID： PMC5460095          DOI： 10.21037/tgh.2017.05.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  19 in total

1.  Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.

Authors:  Monisha Sudarshan; Thierry Alcindor; Steven Ades; Abdullah Aloraini; Marie van Huyse; Jamil Asselah; Marc David; Dominique Frechette; Sonia Brisson; Michael Thirlwell; Lorenzo Ferri
Journal:  Ann Surg Oncol       Date:  2014-07-15       Impact factor: 5.344

2.  Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.

Authors:  Christoph Springfeld; Christiane Wiecha; Romy Kunzmann; Ulrike Heger; Wilko Weichert; Rupert Langer; Annika Stange; Susanne Blank; Leila Sisic; Thomas Schmidt; Florian Lordick; Dirk Jäger; Lars Grenacher; Tom Bruckner; Markus W Büchler; Katja Ott
Journal:  Ann Surg Oncol       Date:  2015-05-22       Impact factor: 5.344

3.  Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.

Authors:  N Fazio; R Biffi; R Maibach; S Hayoz; S Thierstein; P Brauchli; J Bernhard; R Stupp; B Andreoni; G Renne; C Crosta; R Morant; A Chiappa; F Luca; M G Zampino; O Huber; A Goldhirsch; F de Braud; A D Roth
Journal:  Ann Oncol       Date:  2015-12-27       Impact factor: 32.976

4.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

5.  NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.

Authors:  Christoph Schulz; Frank Kullmann; Volker Kunzmann; Martin Fuchs; Michael Geissler; Ursula Vehling-Kaiser; Heribert Stauder; Axel Wein; Salah-Eddin Al-Batran; Thomas Kubin; Claus Schäfer; Sebastian Stintzing; Clemens Giessen; Dominik Paul Modest; Karsten Ridwelski; Volker Heinemann
Journal:  Int J Cancer       Date:  2015-02-25       Impact factor: 7.396

6.  Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.

Authors:  Bhawna Sirohi; Savio George Barreto; Ashish Singh; Swati Batra; Abhishek Mittra; Sameer Rastogia; Mukta Ramadwar; Nitin Shetty; Mahesh Goel; Shailesh V Shrikhande
Journal:  J Cancer Res Ther       Date:  2014 Oct-Dec       Impact factor: 1.805

7.  The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

Authors:  Salah-Eddin Al-Batran; Claudia Pauligk; Nils Homann; Jörg T Hartmann; Markus Moehler; Stephan Probst; Volker Rethwisch; Jan Stoehlmacher-Williams; Nicole Prasnikar; Stephan Hollerbach; Carsten Bokemeyer; Rolf Mahlberg; Ralf D Hofheinz; Kim Luley; Frank Kullmann; Elke Jäger
Journal:  Eur J Cancer       Date:  2012-10-11       Impact factor: 9.162

8.  Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center.

Authors:  Bhawna Sirohi; Sameer Rastogi; Shaheenah Dawood; S Talole; Mukta Ramadwar; Nitin Shetty; Shailesh V Shrikhande
Journal:  Med Oncol       Date:  2014-09-17       Impact factor: 3.064

9.  Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.

Authors:  Yuelu Zhu; Yongkun Sun; Shangying Hu; Yong Jiang; Jiangying Yue; Xuemin Xue; Lin Yang; Liyan Xue
Journal:  BMC Gastroenterol       Date:  2017-03-14       Impact factor: 3.067

10.  A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.

Authors:  N Starling; A Okines; D Cunningham; W Allum; A Wotherspoon; M Benson; J Thompson; J Thomas; G Brown; A Riddell; F Stavridi; S Ashley; J Oates; I Chau
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.